Valproic acid alters angiogenic and trophic gene expression in human prostate cancer models

Anticancer Research

Volumn 36, Issue 10, 2016, Pages 5079-5086

  Chelluri, Raju ^a   Caza, Tiffany ^b   Woodford, Mark R ^a   Reeder, Jay E ^c   Bratslavsky, Gennady ^a   Byler, Timothy ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Histone deacetylase inhibitors; Neovascularization; Pathologic; Prostatic neoplasms; Thrombospondin 1; Valproic acid

Indexed keywords

ANTINEOPLASTIC AGENT; RNA; THROMBOSPONDIN 1; VALPROIC ACID;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL CYCLE REGULATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; LNCAP CELL LINE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; WESTERN BLOTTING; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; VALPROIC ACID;

EID: 84991756967     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: 10.21873/anticanres.11077     Document Type: Article

References (30)

1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin 65: 5-29, 2015.
2. Jain RK: Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26: 605-22, 2014.
3. Isayeva T, Chandra D, Kallman L, Eltoum IE and Ponnazhagan S: Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. Cancer Res 67: 5789-97, 2007.
4. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T and Kelly WK: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1: 194-202, 2001.
5. Ellis L, Hammers H and Pili R: Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 280: 145-53, 2009.
6. Yin D, Ong JM, Hu J, Desmond JC, Kawamata N, Konda BM, Black KL and Koeffler HP: Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res 13: 1045-1052, 2007.
7. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM and Garcia-Manero G: Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110: 2302-2308, 2007.
8. Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG and Heinzel T: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969-6978, 2001.
9. Byler TK, Leocardio D, Shapiro O, Bratslavsky G, Stodgell CJ, Wood RW, Messing EM and Reeder JE: Valproic acid decreases urothelial cancer cell proliferation and induces thrombospondin-1 expression. BMC Urol 12: 1186/1471-12-21, 2012.
10. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A and Speleman F: Accurate normalization of realtime quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034, 2002.
11. Yang L, Egger M, Plattner R, Klocker H and Eder IE: Lovastatin causes diminished PSA secretion by inhibiting AR expression and function in LNCaP prostate cancer cells. Urology 77: 1508 e1-7, 2011.
12. Mollapour M, Bourboulia D, Beebe K, Woodford MR, Polier S, Hoang A, Chelluri R, Li Y, Guo A, Lee MJ, Fotooh-Abadi E, Khan S, Prince T, Miyajima N, Yoshida S, Tsutsumi S, Xu W, Panaretou B, Stetler-Stevenson WG, Bratslavsky G, Trepel JB, Prodromou C and Neckers L: Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitors. Molecular Cell 53: 317-329, 2014.
13. Iacopino F, Urbano R, Graziani G, Muzi A, Navarra P and Sica G: Valproic acid activity in androgen-sensitive and-insensitive human prostate cancer cells. Int J Oncol 32: 1293-1303, 2008.
14. Lawler PR and Lawler J: Molecular basis for the regulation of angiogenesis by thrombospondin-1 and-2. Cold Spring Harbor perspectives in medicine 2: 1-13, 2012.
15. Roberts DD, Isenberg JS, Ridnour LA and Wink DA: Nitric oxide and its gatekeeper thrombospondin-1 in tumor angiogenesis. Clin Cancer Res 13: 795-798, 2007.
16. Vallbo C, Wang W and Damber JE: The expression of thrombospondin-1 in benign prostatic hyperplasia and prostatic intraepithelial neoplasia is decreased in prostate cancer. BJU Int 93: 1339-1343, 2004.
17. Shiojima I and Walsh K: Role of Akt signaling in vascular homeostasis and angiogenesis. Circulation Res 90: 1243-1250, 2002.
18. Pulukuri SM, Paitbandla S, Patel J, Estes N and Rao JS: Epigenetic inactivation of the tissue inhibitor of metalloproteinase-2 (TIMP-2) gene in human prostate tumors. Oncogene 26: 5229-5237, 2007.
19. Kojima S, Inahara M, Suzuki H, Ichikawa T and Furuya Y: Implications of insulin-like growth factor-I for prostate cancer therapies. Int J Urol 16: 161-167, 2009.
20. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D and Adami HO: Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 76: 1115-1118, 1997.
21. Bello-DeOcampo D and Tindall DJ: TGF-beta/Smad signaling in prostate cancer. Curr Drug Targets 4: 197-207, 2003.
22. Li Z, Wang C, Jiao X, Lu Y, Fu M, Quong AA, Dye C, Yang J, Dai M, Ju X, Zhang X, Li A, Burbelo P, Stanley ER and Pestell RG: Cyclin D1 regulates cellular migration through the inhibition of thrombospondin 1 and ROCK signaling. Mol Cell Biol 26: 4240-4256, 2006.
23. Witt D, Burfeind P, von Hardenberg S, Opitz L, Salinas-Riester G, Bremmer F, Schweyer S, Thelen P, Neesen J and Kaulfuss S: Valproic acid inhibits the proliferation of cancer cells by reexpressing cyclin D2. Carcinogenesis 34: 1115-1124, 2013.
24. Shabbeer S, Kortenhorst MS, Kachhap S, Galloway N, Rodriguez R and Carducci MA: Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate 67: 1099-1110, 2007.
25. Sidana A, Wang M, Shabbeer S, Chowdhury WH, Netto G, Lupold SE, Carducci M and Rodriguez R: Mechanism of growth inhibition of prostate cancer xenografts by valproic acid. J Biomed Biotechnol: Article ID: 180363, 2012
26. Sidana A, Wang M, Chowdhury WH, Toubaji A, Shabbeer S, Netto G, Carducci M, Lupold SE and Rodriguez R: Does valproic acid induce neuroendocrine differentiation in prostate cancer? J Biomed Biotechnol: Article ID 607480, 2011.
27. Michaelis M, Michaelis UR, Fleming I, Suhan T, Cinatl J, Blaheta RA, Hoffmann K, Kotchetkov R, Busse R, Nau H and Cinatl J Jr.: Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol 65: 520-527, 2004.
28. Stettner M, Kramer G, Strauss A, Kvitkina T, Ohle S, Kieseier BC and Thelen P: Long-term antiepileptic treatment with histone deacetylase inhibitors may reduce the risk of prostate cancer. Eur J Cancer Prevention 21: 55-64, 2012.
29. Kang H, Gillespie TW, Goodman M, Brodie SA, Brandes M, Ribeiro M, Ramalingam SS, Shin DM, Khuri FR and Brandes JC: Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer. Cancer 120: 1394-1400, 2014.
30. Sharma S, Symanowski J, Wong B, Dino P, Manno P and Vogelzang N: A Phase II clinical trial of oral valproic acid in patients with castration-resistant prostate cancers using an intensive biomarker sampling strategy. Transl Oncol 1: 141-147, 2008